Forty Seven's Series B Round

Forty Seven raised a round of funding on October 17, 2017.

Forty Seven is a clinical-stage immuno-oncology company that is developing therapies licensed from Stanford University targeting cancer immune evasion pathways. The lead program Hu5F9-G4 is a monoclon…

Articles about Forty Seven's Series B Round: